Evidence map›Paper›PMID 32651261›Full record

ArticleCancer research2020

Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.

Hanumantha Rao Madala, Iiro Taneli Helenius, Wen Zhou, Evanna Mills, Yiyun Zhang, Yan Liu, Ana M Metelo, Michelle L Kelley, Surendra Punganuru, Kyung Bo Kim and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Hanumantha Rao MadalaCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.ORCID 0000-0001-8086-3188
Iiro Taneli HeleniusCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Wen ZhouDivision of Nephrology and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8455-6011
Evanna MillsDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yiyun ZhangCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Yan LiuCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Ana M MeteloCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Michelle L KelleyCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Surendra PunganuruDepartment of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Kyung Bo KimCollege of Pharmacy, University of Kentucky, Lexington, Kentucky.ORCID 0000-0003-4744-2466
Benjamin OlenchockDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Eugene RheeDivision of Nephrology and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4804-7583
Andrew M IntlekoferMemorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9046-6549
Othon IliopoulosCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.
Edward ChouchaniDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jing-Ruey Joanna YehCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. jyeh1@mgh.harvard.edu.
Massachusetts General Hospital · USCenter for Cancer Research · USHarvard University · USBrigham and Women's Hospital · USKettering University · USTexas Tech University · USUniversity of Kentucky · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Determining mechanisms of the succinate thermogenesis pathways on UCP1-dependent and UCP1-independent thermogenesisR01DK123095 · NIDDK · DANA-FARBER CANCER INST · PI Edward Thomas Chouchani · 2019 to 2026
$4.2M
Metabolic control of normal and malignant hematopoiesisR37CA251543 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI INTLEKOFER, ANDREW MICHAEL · 2020 to 2025
$3.4M
Chemical Biology of IRP1-HIF2a SignalingR01CA215431 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ILIOPOULOS, OTHON · 2017 to 2021
$3.1M
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumorsR01CA215410 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI YEH, JING-RUEY JOANNA · 2018 to 2022
$2.5M
Hypoxia-induced Metabolic Changes in CancerR01CA160458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ILIOPOULOS, OTHON, STEPHANOPOULOS, GREGORY · 2012 to 2016
$1.6M
Investigating L-2-hydroxyglutarate in normal hematopoiesis and leukemogenesisK08CA201483 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI INTLEKOFER, ANDREW MICHAEL · 2016 to 2020
$887k
NCI NIH HHS K08 CA201483NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA160458NCI NIH HHS R01 CA215410NCI NIH HHS R01 CA215431NCI NIH HHS R37 CA251543NIDDK NIH HHS R01 DK123095
6 · The paper itself

Abstract

Under conditions of inherent or induced mitochondrial dysfunction, cancer cells manifest overlapping metabolic phenotypes, suggesting that they may be targeted via a common approach. Here, we use multiple oxidative phosphorylation (OXPHOS)-competent and incompetent cancer cell pairs to demonstrate that treatment with α-ketoglutarate (aKG) esters elicits rapid death of OXPHOS-deficient cancer cells by elevating intracellular aKG concentrations, thereby sequestering nitrogen from aspartate through glutamic-oxaloacetic transaminase 1 (GOT1). Exhaustion of aspartate in these cells resulted in immediate depletion of adenylates, which plays a central role in mediating mTOR inactivation and inhibition of glycolysis. aKG esters also conferred cytotoxicity in a variety of cancer types if their cell respiration was obstructed by hypoxia or by chemical inhibition of the electron transport chain (ETC), both of which are known to increase aspartate and GOT1 dependencies. Furthermore, preclinical mouse studies suggested that cell-permeable aKG displays a good biosafety profile, eliminates aspartate only in OXPHOS-incompetent tumors, and prevents their growth and metastasis. This study reveals a novel cytotoxic mechanism for the metabolite aKG and identifies cell-permeable aKG, either by itself or in combination with ETC inhibitors, as a potential anticancer approach. SIGNIFICANCE: These findings demonstrate that OXPHOS deficiency caused by either hypoxia or mutations, which can significantly increase cancer virulence, renders tumors sensitive to aKG esters by targeting their dependence upon GOT1 for aspartate synthesis. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/17/3492/F1.large.jpg.

Indexed as

AnimalsCell Line, TumorHumansKetoglutaric AcidsMice, NudeMitochondrial DiseasesNeoplasmsNitrogenOxidative PhosphorylationXenograft Model Antitumor AssaysKetoglutaric AcidsNitrogen

Identifiers

PMID32651261
PMCPMC7484159
OpenAlexW3040876053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.